Lmcg Investments LLC Acquires 25,087 Shares of Johnson & Johnson (NYSE:JNJ)

Lmcg Investments LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 105.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,836 shares of the company's stock after buying an additional 25,087 shares during the period. Lmcg Investments LLC's holdings in Johnson & Johnson were worth $8,099,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Lantz Financial LLC boosted its stake in Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after buying an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter worth about $453,000. Oregon Pacific Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $949,000. Horan Securities Inc. lifted its holdings in Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock valued at $1,038,000 after purchasing an additional 90 shares during the last quarter. Finally, Strategic Financial Concepts LLC boosted its position in Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock valued at $501,000 after buying an additional 1,271 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.9%

Johnson & Johnson stock traded up $1.36 during midday trading on Friday, reaching $155.02. The stock had a trading volume of 5,387,625 shares, compared to its average volume of 7,927,043. The stock has a market capitalization of $372.99 billion, a P/E ratio of 23.31, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The firm's fifty day simple moving average is $153.56 and its 200-day simple moving average is $153.67. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.35%. Johnson & Johnson's payout ratio is 57.84%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on JNJ. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.